九洲药业(603456) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥1,136,105,418.43, representing a year-over-year increase of 53.97%[4] - Net profit attributable to shareholders for Q3 2021 was ¥198,285,197.31, an increase of 80.39% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥190,967,141.35, reflecting a significant increase of 111.40% year-over-year[4] - The basic earnings per share for Q3 2021 was ¥0.24, up 71.43% from the previous year[4] - Total operating revenue for the first three quarters of 2021 reached ¥3,004,229,474.76, a significant increase from ¥1,745,837,089.12 in the same period last year, representing a growth of approximately 72.0%[16] - Operating profit for the third quarter was ¥549,152,950.95, compared to ¥292,668,143.15 in the previous year, indicating an increase of about 87.6%[18] - Net profit attributable to shareholders of the parent company for the third quarter was ¥473,122,148.54, up from ¥239,369,327.15, reflecting a growth of approximately 97.5%[19] - The company reported a total comprehensive income of ¥472,082,866.15 for the third quarter, compared to ¥238,390,876.66 in the previous year, reflecting an increase of about 97.5%[19] Assets and Liabilities - The total assets as of the end of the reporting period amounted to ¥6,452,383,759.21, a 29.00% increase from the end of the previous year[5] - The total assets of the company reached ¥6,452,383,759.21, up from ¥5,001,793,606.73, marking an increase of about 29.1% year-over-year[15] - The total liabilities increased to ¥1,894,307,053.74, compared to ¥1,633,041,040.39 in the previous year, which is an increase of approximately 16%[15] - The total liabilities of the company stood at ¥1,915,677,518.46, with non-current liabilities totaling ¥282,636,478.07[16] - Total liabilities amounted to approximately ¥1,915.68 million, with current liabilities at ¥1,633.04 million and non-current liabilities at ¥282.64 million[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,490, with the largest shareholder, Zhejiang Zhongbei Jiuzhou Group Co., Ltd., holding 283,518,812 shares, accounting for 34.05% of the total[10] - The company has a total of 283,518,812 unrestricted shares held by its largest shareholder, indicating a strong position in the market[10] - Shareholders' equity totaled approximately ¥3,086.12 million, with total equity attributable to the parent company at ¥3,083.21 million[29] Cash Flow - The company reported a net cash flow from operating activities of ¥424,269,362.37, which is a 15.03% increase year-to-date[4] - Cash inflow from operating activities for the first three quarters of 2021 reached CNY 2,797,076,921.77, a significant increase of 54.0% compared to CNY 1,815,441,376.33 in the same period of 2020[21] - The net cash flow from operating activities for the first three quarters of 2021 was CNY 424,269,362.37, up from CNY 368,824,098.67 in 2020, reflecting a growth of 15.0%[21] - Cash inflow from financing activities in the first three quarters of 2021 totaled CNY 2,164,907,585.39, a substantial increase from CNY 971,811,250.00 in 2020, representing a growth of 123.0%[22] - The net cash flow from financing activities for the first three quarters of 2021 was CNY 589,917,139.54, compared to -CNY 9,280,876.43 in 2020, showing a positive turnaround[22] Investments and Acquisitions - The company completed the acquisition of 100% equity in Hangzhou Zhuliang Pharmaceutical Technology Co., Ltd. for ¥22,193,000, making it a wholly-owned subsidiary[12] - The company reported a significant increase in long-term equity investments, rising to ¥59,413,393.35 from ¥12,771,904.78, representing a growth of about 366.5%[14] Operational Costs and Expenses - The total operating cost for the first three quarters was ¥2,472,370,398.44, up from ¥1,508,400,770.52, indicating a rise of approximately 64.0%[16] - Research and development expenses for the third quarter amounted to ¥122,104,944.00, compared to ¥76,294,605.88 in the previous year, marking an increase of about 60.2%[18] Other Financial Metrics - The weighted average return on equity for Q3 2021 was 4.62%, an increase of 0.82 percentage points year-over-year[5] - The company received government subsidies amounting to ¥5,228,196.48 during the reporting period, contributing to its financial performance[6] - The company recognized a right-of-use asset and lease liability of ¥1,799,993.16 due to the implementation of revised accounting standards[29] - The company has short-term borrowings of approximately ¥788.02 million and long-term borrowings of approximately ¥140.19 million[27] - The company reported accounts payable of approximately ¥411.34 million and other payables totaling approximately ¥106.63 million[27]